Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
about
ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the LiteratureRenal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International NetworkTrametinib: a MEK inhibitor for management of metastatic melanomaInhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Therapeutic implications of melanoma heterogeneity.Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials.Targeted agents and combinations in ovarian cancer: where are we now?Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis.Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.Checkpoint inhibitor-induced uveitis: a case series.Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF (V600) mutation-positive solid tumors: a phase 1 study.Tocilizumab in patients with multisystem Erdheim-Chester disease.Melanoma therapy: Check the checkpoints.MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells
P2860
Q26744787-C56555B5-AE8A-4624-97D2-B42D5BF4D630Q26752774-83296745-03B9-4565-B21D-775C4B67B493Q26764883-BA78D2CB-3A44-43C3-A768-03466462DF77Q26782976-A1D832D5-3869-4982-9ED8-9EF66F269C79Q36277440-528ED403-5A79-47FB-857B-8E49C6EB4A6DQ36442499-550B9A30-BB6C-44D4-9C17-E2088D983372Q37149871-D8BD8E7F-487E-44BA-860C-8DE99EFAFD05Q37632230-7AB46168-DB94-4F72-AD2C-24CAA2E544C0Q37689374-49A5B681-5A55-47E1-A4EF-3E2FC20FF4E4Q38700489-D9A53FD8-A00A-40DB-A00E-E052C064550EQ38760610-39F1D56B-7059-49BA-A91B-F07E191EF396Q38793287-213FC2F5-792C-4412-B5F2-7BAD007D5E6AQ38909389-0821C315-B954-4636-8396-21C4A95B0E1DQ38919639-C438AFFA-DF0E-4470-B43A-26E0C752708EQ39040914-403E9248-F192-4DC4-8404-EDFCAFF01895Q39294398-CC667560-F1A3-46AE-AAA0-50ADF3056160Q39319162-826D8BC2-5596-4525-8FE3-0C034D50106AQ41862341-4FB6FDB7-C375-4C9F-A946-99315C7327ABQ41950059-D087D183-4BFB-4A66-A588-0F7051FB5556Q47405465-55751AA7-0238-42ED-AD2E-2BE9A4175926Q48108178-7C47570C-C68D-4CEB-AC75-41F021C547BBQ50086506-F367F5F3-2AAD-410D-8640-B9B7ED1E8B01Q50100664-1661A556-81B8-46DA-9E97-FE045DFB387FQ50209952-0BD15F6A-881D-4F28-96FA-7B0A258F143CQ52763513-BA18AA57-8FC2-401B-B421-43DF13B26D86Q55031619-6FEC6675-225B-4372-8EE4-44CAD0788F01Q58760429-A5ED8D10-8AC5-4684-BAE0-64F49057EE94
P2860
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
@ast
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
@en
type
label
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
@ast
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
@en
prefLabel
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
@ast
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
@en
P2860
P356
P1476
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.
@en
P2093
Pippa G Corrie
Sarah J Welsh
P2860
P304
P356
10.1177/1758834014566428
P577
2015-03-01T00:00:00Z